Furthermore, according The Cancer Genome Atlas (TCGA) genetic amplification of Bcl2 and Bcl2l1 (encoding Bcl-xL) occurs in less than 3% of luminal B and TNBC cases [54], implying that BH3-mimetic targeting of Bcl-2 and Bcl-xL may not be beneficial in most breast cancer subtypes. Here, BCL2L1 is linked to breast carcinoma.